GDNF-Transfected Macrophages Produce Potent Neuroprotective Effects in Parkinson's Disease Mouse Model
暂无分享,去创建一个
Richa Gupta | Alexander V. Kabanov | Elena V. Batrakova | A. Kabanov | E. Batrakova | Zhijian He | J. P. Bohnsack | Richa Gupta | Yuling Zhao | Zhijian He | Matthew J. Haney | Yuling Zhao | John P. Bohnsack
[1] A. Björklund,et al. Ex Vivo Gene Transfer of Brain‐derived Neurotrophic Factor to the Intact Rat Forebrain: Neurotrophic Effects on Cholinergic Neurons , 1996, The European journal of neuroscience.
[2] J. Mallet,et al. Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[3] F. Castellino,et al. Exosomes released from macrophages infected with intracellular pathogens stimulate a proinflammatory response in vitro and in vivo. , 2007, Blood.
[4] F. Gage,et al. Regulatable acetylcholine-producing fibroblasts enhance cognitive performance. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[5] M. Weinand,et al. Microglial and astrocyte chemokines regulate monocyte migration through the blood-brain barrier in human immunodeficiency virus-1 encephalitis. , 1999, The American journal of pathology.
[6] C. Suschek,et al. The role of iNOS in chronic inflammatory processes in vivo: is it damage-promoting, protective, or active at all? , 2004, Current molecular medicine.
[7] H. Mizukami,et al. Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease , 2002, Gene Therapy.
[8] J. Labandeira-Garcia,et al. An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism. , 1997, Brain research. Brain research protocols.
[9] W. H. Oertel,et al. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde tracing and immunocytochemical study in the rat , 1994, Neuroscience.
[10] D. Casper,et al. Enhanced Vascularization and Survival of Neural Transplants with Ex Vivo Angiogenic Gene Transfer , 2002, Cell transplantation.
[11] S. Gillam. The Jeanne Manery Fisher Memorial Lecture 1994. Molecular biology of rubella virus structural proteins. , 1994, Biochemistry and cell biology = Biochimie et biologie cellulaire.
[12] H. Gendelman,et al. Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's disease. , 2010, Nanomedicine.
[13] A. Björklund,et al. Ex vivo nerve growth factor gene transfer to the basal forebrain in presymptomatic middle-aged rats prevents the development of cholinergic neuron atrophy and cognitive impairment during aging. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[14] John L. Hudson,et al. Glial cell line-derived neurotrophic factor augments midbrain dopaminergic circuits in vivo , 1995, Brain Research Bulletin.
[15] J. Jankovic,et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD , 2003, Neurology.
[16] J. Holden,et al. Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF , 2009, Neurobiology of Disease.
[17] Aled Clayton,et al. Isolation and Characterization of Exosomes from Cell Culture Supernatants and Biological Fluids , 2006, Current protocols in cell biology.
[18] J. Kordower,et al. Trophic factors therapy in Parkinson's disease. , 2009, Progress in brain research.
[19] H. Gendelman,et al. Active Targeted Macrophage-mediated Delivery of Catalase to Affected Brain Regions in Models of Parkinson's Disease. , 2011, Journal of nanomedicine & nanotechnology.
[20] A. Björklund,et al. Localized striatal delivery of GDNF as a treatment for Parkinson disease , 2004, Nature Neuroscience.
[21] B. Zlokovic. Outwitting the Blood-Brain Barrier for Therapeutic Purposes: Osmotic Opening and Other Means , 1998 .
[22] V. Perry,et al. Chemokine targets in acute brain injury and disease. , 2001, Progress in brain research.
[23] C. Théry,et al. Membrane vesicles as conveyors of immune responses , 2009, Nature Reviews Immunology.
[24] M. Kameda,et al. Neurorescue effects of VEGF on a rat model of Parkinson's disease , 2005, Brain Research.
[25] I. Gozes. Neuroprotective peptide drug delivery and development: potential new therapeutics , 2001, Trends in Neurosciences.
[26] M. Farrer. Genetics of Parkinson disease: paradigm shifts and future prospects , 2006, Nature Reviews Genetics.
[27] J. Lötvall,et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells , 2007, Nature Cell Biology.
[28] V. Perry,et al. Interleukin-1β-Induced Changes in Blood–Brain Barrier Permeability, Apparent Diffusion Coefficient, and Cerebral Blood Volume in the Rat Brain: A Magnetic Resonance Study , 2000, The Journal of Neuroscience.
[29] K. Khalili,et al. Neuroprotective effects of IGF-I against TNFalpha-induced neuronal damage in HIV-associated dementia. , 2003, Virology.
[30] R. Desnick,et al. Enzyme replacement and enhancement therapies: lessons from lysosomal disorders , 2002, Nature Reviews Genetics.
[31] D. Kirik,et al. Dissociation between short‐term increased graft survival and long‐term functional improvements in Parkinsonian rats overexpressing glial cell line‐derived neurotrophic factor , 2004, The European journal of neuroscience.
[32] R. Johnstone,et al. The Jeanne Manery-Fisher Memorial Lecture 1991. Maturation of reticulocytes: formation of exosomes as a mechanism for shedding membrane proteins. , 1992, Biochemistry and cell biology = Biochimie et biologie cellulaire.
[33] G. Gerhardt,et al. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. , 2005, Journal of neurosurgery.
[34] K. Bankiewicz,et al. Glial-derived neurotrophic factor gene transfer for Parkinson's disease: Anterograde distribution of AAV2 vectors in the primate brain , 2012, Neurobiology of Disease.
[35] H. Gendelman,et al. A macrophage-nanozyme delivery system for Parkinson's disease. , 2007, Bioconjugate chemistry.
[36] K. Mukhida,et al. Erythropoietin and GDNF enhance ventral mesencephalic fiber outgrowth and capillary proliferation following neural transplantation in a rodent model of Parkinson's disease , 2006, The European journal of neuroscience.
[37] P. Jenner,et al. Induction and expression of abnormal involuntary movements is related to the duration of dopaminergic stimulation in 6‐OHDA‐lesioned rats , 2011, The European journal of neuroscience.
[38] W. Banks,et al. Passage of vasoactive intestinal peptide across the blood–brain barrier , 2003, Peptides.
[39] S. Niclou,et al. Ciliary Neurotrophic Factor Cell-Based Delivery Prevents Synaptic Impairment and Improves Memory in Mouse Models of Alzheimer's Disease , 2010, The Journal of Neuroscience.
[40] H. Gendelman,et al. Polyelectrolyte complex optimization for macrophage delivery of redox enzyme nanoparticles. , 2011, Nanomedicine.
[41] G. Kaplan,et al. The selective binding and transmigration of monocytes through the junctional complexes of human endothelium , 1988, The Journal of experimental medicine.
[42] Guiming Li,et al. Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson's disease. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[43] V. Perry,et al. Age-related effects of interleukin-1 beta on polymorphonuclear neutrophil-dependent increases in blood-brain barrier permeability in rats. , 1997, Brain : a journal of neurology.
[44] E. Neuwelt,et al. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. , 1998, Neurosurgery.
[45] Willem Stoorvogel,et al. Activated T cells recruit exosomes secreted by dendritic cells via LFA-1. , 2009, Blood.
[46] E. Snyder,et al. Neuroprotection through Delivery of Glial Cell Line-Derived Neurotrophic Factor by Neural Stem Cells in a Mouse Model of Parkinson's Disease , 2001, The Journal of Neuroscience.
[47] J. Murray-Rust,et al. Distinct structural elements in GDNF mediate binding to GFRalpha1 and activation of the GFRalpha1-c-Ret receptor complex. , 1999, The EMBO journal.
[48] Brinton Rd. A women's health issue: Alzheimer's disease and strategies for maintaining cognitive health. , 1999 .
[49] R. Brinton. A women's health issue: Alzheimer's disease and strategies for maintaining cognitive health. , 1999, International journal of fertility and women's medicine.
[50] D Michiel Pegtel,et al. Exosomes: Fit to deliver small RNA. , 2010, Communicative & integrative biology.
[51] H. Mochizuki,et al. Use of growth factors for the treatment of Parkinson’s disease , 2010, Expert review of neurotherapeutics.
[52] D. Price,et al. Human nerve growth factor prevents degeneration of basal forebrain cholinergic neurons in primates , 1991, Annals of neurology.
[53] W. Sly,et al. Developmentally regulated mannose 6-phosphate receptor-mediated transport of a lysosomal enzyme across the blood-brain barrier. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[54] M. Zöller,et al. Toward tailored exosomes: the exosomal tetraspanin web contributes to target cell selection. , 2012, The international journal of biochemistry & cell biology.
[55] H. Gendelman,et al. Specific Transfection of Inflamed Brain by Macrophages: A New Therapeutic Strategy for Neurodegenerative Diseases , 2013, PloS one.
[56] M. Vila,et al. D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. , 2003, The Journal of clinical investigation.
[57] A. Bachis,et al. Brain‐Derived Neurotrophic Factor Is Neuroprotective against Human Immunodeficiency Virus‐1 Envelope Proteins , 2005, Annals of the New York Academy of Sciences.
[58] A. Björklund,et al. Function recovery following neural transplantation of embryonic septal nuclei in adult rats with septohippocampal lesions , 1982, Nature.
[59] B. Hoffer,et al. Functional recovery in parkinsonian monkeys treated with GDNF , 1996, Nature.
[60] H. Ichinose,et al. Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease , 1999, Neuroscience Letters.
[61] H. Gendelman,et al. Cell-mediated drug delivery , 2011, Expert opinion on drug delivery.
[62] M. Mason,et al. Induction of heat shock proteins in B-cell exosomes , 2005, Journal of Cell Science.
[63] V. Perry,et al. Inflammation in the nervous system , 1995, Current Opinion in Neurobiology.
[64] H. Gendelman,et al. Blood-borne macrophage-neural cell interactions hitchhike on endosome networks for cell-based nanozyme brain delivery. , 2012, Nanomedicine.
[65] H. Gendelman,et al. Macrophages offer a paradigm switch for CNS delivery of therapeutic proteins. , 2014, Nanomedicine.
[66] S. Imam,et al. Bone marrow-derived microglia-based neurturin delivery protects against dopaminergic neurodegeneration in a mouse model of Parkinson's disease , 2013, Neuroscience Letters.
[67] H. Blau,et al. Increased host neuronal survival and motor function in BMT Parkinsonian mice: Involvement of immunosuppression , 2007, The Journal of comparative neurology.
[68] L. Olson,et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo , 1995, Nature.
[69] C. Shults,et al. BDNF attenuates the effects of intrastriatal injection of 6‐hydroxydopamine , 1995, Neuroreport.
[70] R. Shivers,et al. Structural pathways for macromolecular and cellular transport across the blood-brain barrier during inflammatory conditions. Review. , 2004, Histology and histopathology.
[71] H. Gendelman,et al. Cell-mediated transfer of catalase nanoparticles from macrophages to brain endothelial, glial and neuronal cells. , 2011, Nanomedicine.
[72] G. Gerhardt,et al. Glial Cell Line-Derived Neurotrophic Factor Increases Stimulus-Evoked Dopamine Release and Motor Speed in Aged Rhesus Monkeys , 2003, The Journal of Neuroscience.
[73] Jessica K. Alexander,et al. Identification of Two Distinct Macrophage Subsets with Divergent Effects Causing either Neurotoxicity or Regeneration in the Injured Mouse Spinal Cord , 2009, The Journal of Neuroscience.
[74] J. Murray-Rust,et al. Distinct structural elements in GDNF mediate binding to GFRα1 and activation of the GFRα1–c‐Ret receptor complex , 1999 .